Methods of determining the concentration of an analyte in a fluid test sample
-
0Associated
Cases -
0Associated
Defendants -
0Accused
Products -
192Forward
Citations -
0
Petitions -
1
Assignment
First Claim
1. A method of determining the concentration of an analyte in a fluid test sample, the method comprising the acts of:
- providing an electrochemical sensor adapted to measure the analyte in the fluid test sample, the electrochemical sensor having a counter electrode and a working electrode;
sufficiently covering the counter and working electrodes of the electrochemical sensor with the fluid test sample;
applying a first potential between the counter electrode and working electrode for a first predetermined time period;
measuring the current between the counter electrode and working electrode at a plurality of intervals during the first predetermined time period;
recording the times of at least one measurement during the first predetermined time period;
removing or substantially reducing the first potential between the counter electrode and working electrode for a second predetermined time period;
applying a second potential between the counter electrode and working electrode for a third predetermined time period;
measuring the current between the counter electrode and working electrode at least once during the third predetermined time period;
determining the concentration of the analyte in the fluid test sample as a function of the current measured;
calculating an index as a mathematical function of the following variables;
a measured current of the first predetermined time period a recorded time of the first predetermined time period, and a measured current of the third predetermined time period;
comparing the index to at least one predetermined parameter related to the determined concentration of analyte in the fluid test sample to identify when a bias, if any, exceeds a predetermined threshold; and
displaying either an error signal or an analyte concentration depending on the comparison between the index and the at least one predetermined parameter.
1 Assignment
0 Petitions

Accused Products

Abstract
A method of determining the concentration of an analyte in a fluid test sample that includes providing an electrochemical sensor adapted to measure the analyte in the test sample. The test sample sufficiently covers a counter and working electrode of the electrochemical sensor. A first potential is applied between the counter and working electrodes for a first predetermined time period and the current is measured and the time is recorded. After the first potential is removed or substantially reduced, a second potential is applied between the counter and working electrodes and the current is measured. The concentration of the analyte is determined in the test sample as a function of the current measured. An index is calculated and compared to at least one predetermined parameter to identify when a bias, if any, exceeds a threshold. An error signal or analyte concentration is displayed depending on the comparison.
205 Citations
Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge | ||
Patent #
US 7,909,775 B2
Filed 06/26/2007
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Pelikan Technologies Inc.
|
Method and apparatus for penetrating tissue | ||
Patent #
US 7,914,465 B2
Filed 02/08/2007
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Pelikan Technologies Inc.
|
Method and apparatus for penetrating tissue | ||
Patent #
US 7,909,774 B2
Filed 02/13/2007
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Pelikan Technologies Inc.
|
Method and apparatus for body fluid sampling and analyte sensing | ||
Patent #
US 7,892,183 B2
Filed 07/03/2003
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Pelikan Technologies Inc.
|
Body fluid sampling module with a continuous compression tissue interface surface | ||
Patent #
US 7,862,520 B2
Filed 06/20/2008
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Pelikan Technologies Inc.
|
Method and apparatus for penetrating tissue | ||
Patent #
US 7,901,362 B2
Filed 12/31/2002
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Pelikan Technologies Inc.
|
System and methods for automatically recognizing a control solution | ||
Patent #
US 7,909,983 B2
Filed 05/04/2006
|
Current Assignee
Trividia Health Inc.
|
Sponsoring Entity
Nipro Diagnostics Inc.
|
Method and apparatus for penetrating tissue | ||
Patent #
US 7,874,994 B2
Filed 10/16/2006
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Pelikan Technologies Inc.
|
Method and apparatus for penetrating tissue | ||
Patent #
US 7,909,778 B2
Filed 04/20/2007
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Pelikan Technologies Inc.
|
Method and apparatus for penetrating tissue | ||
Patent #
US 7,909,777 B2
Filed 09/29/2006
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Pelikan Technologies Inc.
|
Underfill Recognition System for a Biosensor | ||
Patent #
US 20110108440A1
Filed 10/22/2010
|
Current Assignee
Ascensia Diabetes Care Holdings AG
|
Sponsoring Entity
Ascensia Diabetes Care Holdings AG
|
Method and apparatus for penetrating tissue | ||
Patent #
US 7,938,787 B2
Filed 09/29/2006
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Pelikan Technologies Inc.
|
Detecting incomplete fill of biosensors | ||
Patent #
US 7,945,394 B2
Filed 06/16/2005
|
Current Assignee
Ascensia Diabetes Care Holdings AG
|
Sponsoring Entity
Bayer Healthcare LLC
|
Systems, Devices, and Methods for Improving Accuracy of Biosensors Using Fill Time | ||
Patent #
US 20110155589A1
Filed 12/17/2010
|
Current Assignee
LifeScan IP Holdings LLC
|
Sponsoring Entity
LifeScan IP Holdings LLC
|
Method and apparatus for penetrating tissue | ||
Patent #
US 7,959,582 B2
Filed 03/21/2007
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Pelikan Technologies Inc.
|
Transient decay amperometry | ||
Patent #
US 8,026,104 B2
Filed 10/21/2007
|
Current Assignee
Ascensia Diabetes Care Holdings AG
|
Sponsoring Entity
Bayer Healthcare LLC
|
Method and apparatus for penetrating tissue | ||
Patent #
US 8,007,446 B2
Filed 10/19/2006
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Method and apparatus for a multi-use body fluid sampling device with sterility barrier release | ||
Patent #
US 7,988,644 B2
Filed 03/21/2007
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Tissue penetration device | ||
Patent #
US 8,016,774 B2
Filed 12/22/2005
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Methods and apparatus for lancet actuation | ||
Patent #
US 7,981,056 B2
Filed 06/18/2007
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Pelikan Technologies Inc.
|
Device and method for variable speed lancet | ||
Patent #
US 7,976,476 B2
Filed 03/16/2007
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Pelikan Technologies Inc.
|
Tissue penetration device | ||
Patent #
US 7,981,055 B2
Filed 12/22/2005
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Pelikan Technologies Inc.
|
Oxidizable species as an internal reference in control solutions for biosensors | ||
Patent #
US 8,002,965 B2
Filed 04/07/2006
|
Current Assignee
Ascensia Diabetes Care Holdings AG
|
Sponsoring Entity
Bayer Healthcare LLC
|
Residual Compensation Including Underfill Error | ||
Patent #
US 20110231105A1
Filed 03/22/2011
|
Current Assignee
Ascensia Diabetes Care Holdings AG
|
Sponsoring Entity
Ascensia Diabetes Care Holdings AG
|
Electrochemical test sensor | ||
Patent #
US 7,993,512 B2
Filed 07/05/2007
|
Current Assignee
Ascensia Diabetes Care Holdings AG
|
Sponsoring Entity
Bayer Healthcare LLC
|
Self optimizing lancing device with adaptation means to temporal variations in cutaneous properties | ||
Patent #
US 7,988,645 B2
Filed 05/03/2007
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Method and apparatus for penetrating tissue | ||
Patent #
US 8,062,231 B2
Filed 10/11/2006
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
METHOD OF REDUCING INTERFERENCES IN AN ELECTROCHEMICAL SENSOR USING TWO DIFFERENT APPLIED POTENTIALS | ||
Patent #
US 20100018878A1
Filed 10/06/2009
|
Current Assignee
LifeScan Scotland Limited
|
Sponsoring Entity
LifeScan Scotland Limited
|
Method and apparatus for penetrating tissue | ||
Patent #
US 7,833,171 B2
Filed 02/13/2007
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Pelikan Technologies Inc.
|
Method and apparatus for penetrating tissue | ||
Patent #
US 7,731,729 B2
Filed 02/13/2007
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Pelikan Technologies Inc.
|
Meter for use in an improved method of reducing interferences in an electrochemical sensor using two different applied potentials | ||
Patent #
US 7,655,119 B2
Filed 10/29/2004
|
Current Assignee
LifeScan IP Holdings LLC
|
Sponsoring Entity
LifeScan Scotland Limited
|
Blood sampling apparatus and method | ||
Patent #
US 7,682,318 B2
Filed 06/12/2002
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Pelikan Technologies Inc.
|
Method and apparatus for a multi-use body fluid sampling device with optical analyte sensing | ||
Patent #
US 7,713,214 B2
Filed 12/18/2002
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Pelikan Technologies Inc.
|
Method of reducing the effect of direct interference current in an electrochemical test strip | ||
Patent #
US 7,653,492 B2
Filed 10/29/2004
|
Current Assignee
LifeScan IP Holdings LLC
|
Sponsoring Entity
LifeScan Scotland Limited
|
Method and apparatus for improving success rate of blood yield from a fingerstick | ||
Patent #
US 7,699,791 B2
Filed 06/12/2002
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Pelikan Technologies Inc.
|
Tissue penetration device | ||
Patent #
US 7,841,992 B2
Filed 12/22/2005
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Pelikan Technologies Inc.
|
Method and apparatus for penetrating tissue | ||
Patent #
US 7,648,468 B2
Filed 12/31/2002
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Pelikan Technologies Inc.
|
Cassette of lancet cartridges for sampling blood | ||
Patent #
US 7,666,149 B2
Filed 10/28/2002
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Pelikan Technologies Inc.
|
Method and apparatus for penetrating tissue | ||
Patent #
US 7,674,232 B2
Filed 12/31/2002
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Pelikan Technologies Inc.
|
Method and apparatus for penetrating tissue | ||
Patent #
US 7,717,863 B2
Filed 12/31/2002
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Pelikan Technologies Inc.
|
Fluid sampling device with improved analyte detecting member configuration | ||
Patent #
US 7,822,454 B1
Filed 01/03/2005
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Pelikan Technologies Inc.
|
Tissue penetration device | ||
Patent #
US 7,850,622 B2
Filed 12/22/2005
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Pelikan Technologies Inc.
|
Method and apparatus for body fluid sampling and analyte sensing | ||
Patent #
US 7,850,621 B2
Filed 06/07/2004
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Pelikan Technologies Inc.
|
Oxidizable Species as an Internal Reference in Control Solutions for Biosensors | ||
Patent #
US 20090014339A1
Filed 04/07/2006
|
Current Assignee
Ascensia Diabetes Care Holdings AG
|
Sponsoring Entity
Ascensia Diabetes Care Holdings AG
|
Method and apparatus for penetrating tissue | ||
Patent #
US 7,481,776 B2
Filed 12/31/2002
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Pelikan Technologies Inc.
|
Method and apparatus for penetrating tissue | ||
Patent #
US 7,491,178 B2
Filed 12/31/2002
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Pelikan Technologies Inc.
|
Method and apparatus for penetrating tissue | ||
Patent #
US 7,524,293 B2
Filed 12/31/2002
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Pelikan Technologies Inc.
|
Integrated blood sampling analysis system with multi-use sampling module | ||
Patent #
US 7,537,571 B2
Filed 06/12/2002
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Pelikan Technologies Inc.
|
Method and apparatus for penetrating tissue | ||
Patent #
US 7,547,287 B2
Filed 12/31/2002
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Pelikan Technologies Inc.
|
SYSTEM AND METHOD FOR MEASURING AN ANALYTE IN A SAMPLE | ||
Patent #
US 20090184004A1
Filed 01/06/2009
|
Current Assignee
LifeScan IP Holdings LLC
|
Sponsoring Entity
LifeScan IP Holdings LLC
|
Slope-Based Compensation | ||
Patent #
US 20090177406A1
Filed 12/08/2008
|
Current Assignee
Ascensia Diabetes Care Holdings AG
|
Sponsoring Entity
Ascensia Diabetes Care Holdings AG
|
Method and apparatus for penetrating tissue | ||
Patent #
US 7,563,232 B2
Filed 12/31/2002
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Pelikan Technologies Inc.
|
Method and apparatus for penetrating tissue | ||
Patent #
US 7,582,099 B2
Filed 12/31/2002
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Pelikan Technologies Inc.
|
Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means | ||
Patent #
US 7,582,063 B2
Filed 11/21/2001
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Pelikan Technologies Inc.
|
Method and apparatus for a point of care device | ||
Patent #
US 7,604,592 B2
Filed 06/14/2004
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Pelikan Technologies Inc.
|
Method of reducing interferences in an electrochemical sensor using two different applied potentials | ||
Patent #
US 7,618,522 B2
Filed 10/29/2004
|
Current Assignee
LifeScan IP Holdings LLC
|
Sponsoring Entity
LifeScan Scotland Limited
|
Electrochemical test sensor | ||
Patent #
US 20080011616A1
Filed 07/05/2007
|
Current Assignee
Ascensia Diabetes Care Holdings AG
|
Sponsoring Entity
Ascensia Diabetes Care Holdings AG
|
Self optimizing lancing device with adaptation means to temporal variations in cutaneous properties | ||
Patent #
US 7,316,700 B2
Filed 06/12/2002
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Pelikan Technologies Inc.
|
Detecting Incomplete Fill of Biosensors | ||
Patent #
US 20080033667A1
Filed 06/16/2005
|
Current Assignee
Ascensia Diabetes Care Holdings AG
|
Sponsoring Entity
Ascensia Diabetes Care Holdings AG
|
Method and apparatus for lancet actuation | ||
Patent #
US 7,344,507 B2
Filed 09/05/2002
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Pelikan Technologies Inc.
|
Thermal regulation of fluidic samples within a diagnostic cartridge | ||
Patent #
US 7,344,894 B2
Filed 10/16/2001
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Agilent Technologies Incorporated
|
Method and apparatus for penetrating tissue | ||
Patent #
US 7,374,544 B2
Filed 12/31/2002
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Pelikan Technologies Inc.
|
Method and apparatus for penetrating tissue | ||
Patent #
US 7,410,468 B2
Filed 12/31/2002
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Pelikan Technologies Inc.
|
SYSTEMS AND METHODS FOR CONCENTRATING SUBSTANCES IN FLUID SAMPLES | ||
Patent #
US 20080237142A1
Filed 04/02/2007
|
Current Assignee
Battelle Energy Alliance LLC
|
Sponsoring Entity
Battelle Energy Alliance LLC
|
System and methods for providing corrected analyte concentration measurements | ||
Patent #
US 20070235346A1
Filed 04/11/2006
|
Current Assignee
Nipro Diagnostics Inc.
|
Sponsoring Entity
Nipro Diagnostics Inc.
|
Method of Reducing the Effect of Direct Interference Current in an Electrochemical Test Strip | ||
Patent #
US 20070276621A1
Filed 10/29/2004
|
Current Assignee
LifeScan IP Holdings LLC
|
Sponsoring Entity
LifeScan IP Holdings LLC
|
Method and apparatus for body fluid sampling with improved sensing | ||
Patent #
US 7,297,151 B2
Filed 05/02/2003
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Pelikan Technologies Inc.
|
System and methods for automatically recognizing a control solution | ||
Patent #
US 20070256943A1
Filed 05/04/2006
|
Current Assignee
Trividia Health Inc.
|
Sponsoring Entity
Trividia Health Inc.
|
Meter for use in an improved method of reducing interferences in an electrochemical sensor using two different applied potentials | ||
Patent #
US 20050109618A1
Filed 10/29/2004
|
Current Assignee
LifeScan IP Holdings LLC
|
Sponsoring Entity
LifeScan IP Holdings LLC
|
Method of reducing interferences in an electrochemical sensor using two different applied potentials | ||
Patent #
US 20050183965A1
Filed 10/29/2004
|
Current Assignee
LifeScan IP Holdings LLC
|
Sponsoring Entity
LifeScan IP Holdings LLC
|
Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge | ||
Patent #
US 8,123,700 B2
Filed 06/26/2007
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Methods and apparatus for lancet actuation | ||
Patent #
US 8,079,960 B2
Filed 10/10/2006
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Tissue penetration device | ||
Patent #
US 8,162,853 B2
Filed 12/22/2005
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Method and apparatus for penetrating tissue | ||
Patent #
US 8,197,421 B2
Filed 07/16/2007
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Method and apparatus for penetrating tissue | ||
Patent #
US 8,197,423 B2
Filed 12/14/2010
|
Current Assignee
Pelikan Technologies Inc.
|
Sponsoring Entity
Pelikan Technologies Inc.
|
Tissue penetration device | ||
Patent #
US 8,206,317 B2
Filed 12/22/2005
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Tissue penetration device | ||
Patent #
US 8,206,319 B2
Filed 08/26/2010
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Tissue penetration device | ||
Patent #
US 8,211,037 B2
Filed 12/22/2005
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Tissue penetration device | ||
Patent #
US 8,216,154 B2
Filed 12/23/2005
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Method and apparatus for penetrating tissue | ||
Patent #
US 8,221,334 B2
Filed 12/22/2010
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Method and apparatus for body fluid sampling and analyte sensing | ||
Patent #
US 8,251,921 B2
Filed 06/10/2010
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Method and apparatus for body fluid sampling with hybrid actuation | ||
Patent #
US 8,267,870 B2
Filed 05/30/2003
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Method and apparatus for an improved sample capture device | ||
Patent #
US 8,282,576 B2
Filed 09/29/2004
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge | ||
Patent #
US 8,282,577 B2
Filed 06/15/2007
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Method of manufacturing a fluid sampling device with improved analyte detecting member configuration | ||
Patent #
US 8,296,918 B2
Filed 08/23/2010
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Tissue penetration device | ||
Patent #
US 8,333,710 B2
Filed 10/05/2005
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Tissue penetration device | ||
Patent #
US 8,337,419 B2
Filed 10/04/2005
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Tissue penetration device | ||
Patent #
US 8,337,420 B2
Filed 03/24/2006
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Tissue penetration device | ||
Patent #
US 8,343,075 B2
Filed 12/23/2005
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Electrochemical test sensor | ||
Patent #
US 8,343,332 B2
Filed 06/16/2011
|
Current Assignee
Ascensia Diabetes Care Holdings AG
|
Sponsoring Entity
Bayer Healthcare LLC
|
Tissue penetration device | ||
Patent #
US 8,360,991 B2
Filed 12/23/2005
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Method and apparatus for penetrating tissue | ||
Patent #
US 8,382,682 B2
Filed 02/06/2007
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Tissue penetration device | ||
Patent #
US 8,382,683 B2
Filed 03/07/2012
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Method and apparatus for multi-use body fluid sampling device with sterility barrier release | ||
Patent #
US 8,388,551 B2
Filed 05/27/2008
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Method and apparatus for penetrating tissue | ||
Patent #
US 8,403,864 B2
Filed 05/01/2006
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Gated voltammetry | ||
Patent #
US 8,404,100 B2
Filed 02/26/2008
|
Current Assignee
Ascensia Diabetes Care Holdings AG
|
Sponsoring Entity
Bayer Healthcare LLC
|
Methods and apparatus for lancet actuation | ||
Patent #
US 8,414,503 B2
Filed 03/16/2007
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Gated amperometry | ||
Patent #
US 8,425,757 B2
Filed 12/19/2007
|
Current Assignee
Ascensia Diabetes Care Holdings AG
|
Sponsoring Entity
Bayer Healthcare LLC
|
Method and apparatus for a multi-use body fluid sampling device with sterility barrier release | ||
Patent #
US 8,430,828 B2
Filed 01/26/2007
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Method and apparatus for penetrating tissue | ||
Patent #
US 8,435,190 B2
Filed 01/19/2007
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Apparatus and method for penetration with shaft having a sensor for sensing penetration depth | ||
Patent #
US 8,439,872 B2
Filed 04/26/2010
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Systems and methods for discriminating control solution from a physiological sample | ||
Patent #
US 8,449,740 B2
Filed 07/21/2010
|
Current Assignee
LifeScan IP Holdings LLC
|
Sponsoring Entity
Lifescan Incorporated
|
Transient decay amperometry | ||
Patent #
US 8,470,604 B2
Filed 08/16/2011
|
Current Assignee
Ascensia Diabetes Care Holdings AG
|
Sponsoring Entity
Bayer Healthcare LLC
|
Systems and methods for discriminating control solution from a physiological sample | ||
Patent #
US 8,529,751 B2
Filed 03/31/2006
|
Current Assignee
LifeScan IP Holdings LLC
|
Sponsoring Entity
Lifescan Incorporated
|
System and method for measuring an analyte in a sample | ||
Patent #
US 8,551,320 B2
Filed 05/13/2009
|
Current Assignee
LifeScan IP Holdings LLC
|
Sponsoring Entity
LIFESCAN DIVISION OF CILAG GMBH INTERNATIONAL
|
Method and apparatus for penetrating tissue | ||
Patent #
US 8,579,831 B2
Filed 10/06/2006
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
System and method for measuring an analyte in a sample | ||
Patent #
US 8,603,768 B2
Filed 01/06/2009
|
Current Assignee
LifeScan IP Holdings LLC
|
Sponsoring Entity
Lifescan Incorporated
|
Tissue penetration device | ||
Patent #
US 8,622,930 B2
Filed 07/18/2011
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Systems, devices, and methods for improving accuracy of biosensors using fill time | ||
Patent #
US 8,623,198 B2
Filed 12/17/2010
|
Current Assignee
LifeScan IP Holdings LLC
|
Sponsoring Entity
Lifescan Incorporated
|
Method and apparatus for penetrating tissue | ||
Patent #
US 8,202,231 B2
Filed 04/23/2007
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Sampling module device and method | ||
Patent #
US 8,641,643 B2
Filed 04/27/2006
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Gated voltammetry devices | ||
Patent #
US 8,647,489 B2
Filed 02/28/2013
|
Current Assignee
Ascensia Diabetes Care Holdings AG
|
Sponsoring Entity
Bayer Healthcare LLC
|
Method and apparatus for improving fluidic flow and sample capture | ||
Patent #
US 8,668,656 B2
Filed 12/31/2004
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Underfill recognition system for a biosensor | ||
Patent #
US 8,668,819 B2
Filed 10/22/2010
|
Current Assignee
Ascensia Diabetes Care Holdings AG
|
Sponsoring Entity
Bayer Healthcare LLC
|
Tissue penetration device | ||
Patent #
US 8,679,033 B2
Filed 06/16/2011
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Method and apparatus for penetrating tissue | ||
Patent #
US 8,690,796 B2
Filed 09/29/2006
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Method and apparatus for analyte measurement test time | ||
Patent #
US 8,652,831 B2
Filed 03/26/2008
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Analyte measurement device with a single shot actuator | ||
Patent #
US 8,702,624 B2
Filed 01/29/2010
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Oxidizable species as an internal reference in control solutions for biosensors | ||
Patent #
US 8,702,926 B2
Filed 07/11/2011
|
Current Assignee
Ascensia Diabetes Care Holdings AG
|
Sponsoring Entity
Bayer Healthcare LLC
|
System and method for measuring an analyte in a sample | ||
Patent #
US 8,709,739 B2
Filed 09/14/2012
|
Current Assignee
LifeScan IP Holdings LLC
|
Sponsoring Entity
Lifescan Incorporated
|
Electric lancet actuator | ||
Patent #
US 8,721,671 B2
Filed 07/06/2005
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Method for determining analyte concentration based on complex index functions | ||
Patent #
US 8,744,776 B2
Filed 06/06/2011
|
Current Assignee
Ascensia Diabetes Care Holdings AG
|
Sponsoring Entity
Bayer Healthcare LLC
|
Systems and methods of discriminating control solution from a physiological sample | ||
Patent #
US 8,778,168 B2
Filed 09/16/2008
|
Current Assignee
LifeScan IP Holdings LLC
|
Sponsoring Entity
Lifescan Incorporated
|
Printable hydrogels for biosensors | ||
Patent #
US 8,828,203 B2
Filed 05/20/2005
|
Current Assignee
Sanofi S.A.
|
Sponsoring Entity
Sanofi S.A.
|
Tissue penetration device | ||
Patent #
US 8,845,550 B2
Filed 12/03/2012
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Gated amperometry methods | ||
Patent #
US 8,877,035 B2
Filed 03/28/2013
|
Current Assignee
Ascensia Diabetes Care Holdings AG
|
Sponsoring Entity
Bayer Healthcare LLC
|
Systems, devices, and methods for measuring whole blood hematocrit based on initial fill velocity | ||
Patent #
US 8,877,034 B2
Filed 12/30/2009
|
Current Assignee
LifeScan IP Holdings LLC
|
Sponsoring Entity
Lifescan Incorporated
|
Method and apparatus for penetrating tissue | ||
Patent #
US 8,905,945 B2
Filed 03/29/2012
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
System and method for measuring an analyte in a sample | ||
Patent #
US 8,916,040 B2
Filed 09/14/2012
|
Current Assignee
LifeScan IP Holdings LLC
|
Sponsoring Entity
Lifescan Incorporated
|
Method and apparatus for an improved sample capture device | ||
Patent #
US 8,945,910 B2
Filed 06/19/2012
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Electrochemical analyte measurement method and system | ||
Patent #
US 8,962,270 B2
Filed 03/30/2011
|
Current Assignee
LifeScan IP Holdings LLC
|
Sponsoring Entity
LifeScan Scotland Limited
|
Tissue penetration device | ||
Patent #
US 8,965,476 B2
Filed 04/18/2011
|
Current Assignee
Pelikan Technologies Inc.
|
Sponsoring Entity
Pelikan Technologies Inc.
|
Underfill detection system for a biosensor | ||
Patent #
US 8,973,422 B2
Filed 05/13/2011
|
Current Assignee
Ascensia Diabetes Care Holdings AG
|
Sponsoring Entity
Bayer Healthcare LLC
|
Transient decay amperometry biosensors | ||
Patent #
US 9,005,527 B2
Filed 05/29/2013
|
Current Assignee
Ascensia Diabetes Care Holdings AG
|
Sponsoring Entity
Bayer Healthcare LLC
|
Method and apparatus using optical techniques to measure analyte levels | ||
Patent #
US 9,034,639 B2
Filed 06/26/2012
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Method and apparatus for penetrating tissue | ||
Patent #
US 9,072,842 B2
Filed 07/31/2013
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Analyte measurement device with a single shot actuator | ||
Patent #
US 9,089,294 B2
Filed 01/16/2014
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Method and apparatus for penetrating tissue | ||
Patent #
US 9,089,678 B2
Filed 05/21/2012
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Gated voltammetry methods | ||
Patent #
US 9,110,013 B2
Filed 12/20/2013
|
Current Assignee
Ascensia Diabetes Care Holdings AG
|
Sponsoring Entity
Ascensia Diabetes Care Holdings AG
|
Low pain penetrating member | ||
Patent #
US 9,144,401 B2
Filed 12/12/2005
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Systems and methods of discriminating control solution from a physiological sample | ||
Patent #
US 9,157,110 B2
Filed 09/12/2012
|
Current Assignee
LifeScan IP Holdings LLC
|
Sponsoring Entity
Lifescan Incorporated
|
Slope-based compensation including secondary output signals | ||
Patent #
US 9,164,076 B2
Filed 05/27/2011
|
Current Assignee
Ascensia Diabetes Care Holdings AG
|
Sponsoring Entity
Ascensia Diabetes Care Holdings AG
|
Method and apparatus for penetrating tissue | ||
Patent #
US 9,186,468 B2
Filed 01/14/2014
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Biological sample measuring device | ||
Patent #
US 9,213,015 B2
Filed 02/20/2012
|
Current Assignee
PHC Holdings Corporation
|
Sponsoring Entity
Panasonic Healthcare Holdings Co. Ltd.
|
Underfill management system for a biosensor | ||
Patent #
US 9,222,910 B2
Filed 06/07/2011
|
Current Assignee
Ascensia Diabetes Care Holdings AG
|
Sponsoring Entity
Ascensia Diabetes Care Holdings AG
|
Body fluid sampling module with a continuous compression tissue interface surface | ||
Patent #
US 9,226,699 B2
Filed 11/09/2010
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Underfill recognition biosensor | ||
Patent #
US 9,234,866 B2
Filed 01/21/2014
|
Current Assignee
Ascensia Diabetes Care Holdings AG
|
Sponsoring Entity
Ascensia Diabetes Care Holdings AG
|
Oxidizable species as an internal reference in control solutions for biosensors | ||
Patent #
US 9,244,078 B2
Filed 01/29/2014
|
Current Assignee
Ascensia Diabetes Care Holdings AG
|
Sponsoring Entity
Ascensia Diabetes Care Holdings AG
|
Tissue penetration device | ||
Patent #
US 9,248,267 B2
Filed 07/18/2013
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Printable hydrogel for biosensors | ||
Patent #
US 9,261,476 B2
Filed 04/01/2014
|
Current Assignee
Sanofi-Aventis SA
|
Sponsoring Entity
Sanofi-Aventis SA
|
Systems and methods of discriminating control solution from a physiological sample | ||
Patent #
US 9,274,078 B2
Filed 06/21/2013
|
Current Assignee
LifeScan IP Holdings LLC
|
Sponsoring Entity
Lifescan Incorporated
|
Analyzing device, sensor testing device, testing method and computer-readable storage medium | ||
Patent #
US 9,297,777 B2
Filed 02/02/2012
|
Current Assignee
ARKRAY Inc
|
Sponsoring Entity
ARKRAY Inc
|
Tissue penetration device | ||
Patent #
US 9,314,194 B2
Filed 01/11/2007
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Biological sample measuring device and method for measuring biological sample using same | ||
Patent #
US 9,316,649 B2
Filed 05/10/2012
|
Current Assignee
PHC Holdings Corporation
|
Sponsoring Entity
Panasonic Healthcare Holdings Co. Ltd.
|
Method and apparatus for a variable user interface | ||
Patent #
US 9,351,680 B2
Filed 10/14/2004
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Cam drive for managing disposable penetrating member actions with a single motor and motor and control system | ||
Patent #
US 9,375,169 B2
Filed 01/29/2010
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Method and apparatus for analyte detecting device | ||
Patent #
US 9,386,944 B2
Filed 04/10/2009
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Systems, devices and methods for improving accuracy of biosensors using fill time | ||
Patent #
US 9,404,888 B2
Filed 11/26/2013
|
Current Assignee
LifeScan IP Holdings LLC
|
Sponsoring Entity
Lifescan Incorporated
|
Method of using a biosensor | ||
Patent #
US 9,410,917 B2
Filed 02/28/2014
|
Current Assignee
Ascensia Diabetes Care Holdings AG
|
Sponsoring Entity
Ascensia Diabetes Care Holdings AG
|
Tissue penetration device | ||
Patent #
US 9,427,532 B2
Filed 09/29/2014
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Method for penetrating tissue | ||
Patent #
US 9,498,160 B2
Filed 09/29/2014
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Analyte measurement method and system | ||
Patent #
US 9,500,618 B2
Filed 01/27/2015
|
Current Assignee
LifeScan IP Holdings LLC
|
Sponsoring Entity
LifeScan Scotland Limited
|
Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means | ||
Patent #
US 9,560,993 B2
Filed 12/20/2013
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Method and apparatus for improving fluidic flow and sample capture | ||
Patent #
US 9,561,000 B2
Filed 12/10/2013
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Systems and methods for replacing signal artifacts in a glucose sensor data stream | ||
Patent #
US 9,649,069 B2
Filed 06/29/2016
|
Current Assignee
DexCom Incorporated
|
Sponsoring Entity
DexCom Incorporated
|
Underfill recognition biosensor | ||
Patent #
US 9,658,187 B2
Filed 12/02/2015
|
Current Assignee
Ascensia Diabetes Care Holdings AG
|
Sponsoring Entity
Ascensia Diabetes Care Holdings AG
|
Sampling module device and method | ||
Patent #
US 9,694,144 B2
Filed 12/03/2013
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Method and apparatus for penetrating tissue | ||
Patent #
US 9,724,021 B2
Filed 12/08/2014
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Systems and methods for replacing signal artifacts in a glucose sensor data stream | ||
Patent #
US 9,724,045 B1
Filed 04/06/2017
|
Current Assignee
DexCom Incorporated
|
Sponsoring Entity
DexCom Incorporated
|
System and method for measuring an analyte in a sample | ||
Patent #
US 9,739,749 B2
Filed 12/19/2014
|
Current Assignee
LifeScan IP Holdings LLC
|
Sponsoring Entity
Lifescan Incorporated
|
Signal processing for continuous analyte sensor | ||
Patent #
US 9,750,441 B2
Filed 08/15/2016
|
Current Assignee
DexCom Incorporated
|
Sponsoring Entity
DexCom Incorporated
|
Systems and methods for replacing signal artifacts in a glucose sensor data stream | ||
Patent #
US 9,750,460 B2
Filed 04/14/2017
|
Current Assignee
DexCom Incorporated
|
Sponsoring Entity
DexCom Incorporated
|
Oxidizable species as an internal reference in control solutions for biosensors | ||
Patent #
US 9,766,198 B2
Filed 12/10/2015
|
Current Assignee
Ascensia Diabetes Care Holdings AG
|
Sponsoring Entity
Ascensia Diabetes Care Holdings AG
|
Analysis compensation including segmented signals | ||
Patent #
US 9,775,806 B2
Filed 09/20/2012
|
Current Assignee
Ascensia Diabetes Care Holdings AG
|
Sponsoring Entity
Ascensia Diabetes Care Holdings AG
|
System and method for measuring an analyte in a sample | ||
Patent #
US 9,784,707 B2
Filed 09/14/2012
|
Current Assignee
LifeScan IP Holdings LLC
|
Sponsoring Entity
Cilag Gmbh International
|
Method and apparatus for penetrating tissue | ||
Patent #
US 9,795,334 B2
Filed 07/09/2007
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Methods and apparatus for lancet actuation | ||
Patent #
US 9,795,747 B2
Filed 06/02/2011
|
Current Assignee
Pelikan Technologies Inc.
|
Sponsoring Entity
Pelikan Technologies Inc.
|
Methods and apparatus for lancet actuation | ||
Patent #
US 9,802,007 B2
Filed 11/18/2013
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Method and apparatus for a fluid sampling device | ||
Patent #
US 9,820,684 B2
Filed 06/03/2005
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Devices using gated voltammetry methods | ||
Patent #
US 9,835,582 B2
Filed 07/10/2015
|
Current Assignee
Ascensia Diabetes Care Holdings AG
|
Sponsoring Entity
Ascensia Diabetes Care Holdings AG
|
Body fluid sampling device with capacitive sensor | ||
Patent #
US 9,839,386 B2
Filed 06/12/2014
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Systems, devices, and methods for measuring whole blood hematocrit based on initial fill velocity | ||
Patent #
US 9,927,388 B2
Filed 10/10/2014
|
Current Assignee
LifeScan IP Holdings LLC
|
Sponsoring Entity
Lifescan Incorporated
|
Method of using an electrochemical test sensor | ||
Patent #
US 9,933,385 B2
Filed 09/19/2014
|
Current Assignee
Ascensia Diabetes Care Holdings AG
|
Sponsoring Entity
Ascensia Diabetes Care Holdings AG
|
Underfill detection system for a biosensor | ||
Patent #
US 9,939,406 B2
Filed 02/02/2015
|
Current Assignee
Ascensia Diabetes Care Holdings AG
|
Sponsoring Entity
Ascensia Diabetes Care Holdings AG
|
Slope-base compensation including secondary output signals | ||
Patent #
US 9,995,702 B2
Filed 09/04/2015
|
Current Assignee
Ascensia Diabetes Care Holdings AG
|
Sponsoring Entity
Ascensia Diabetes Care Holdings AG
|
Low pain penetrating member | ||
Patent #
US 10,034,628 B2
Filed 12/20/2012
|
Current Assignee
Sanofi-Aventis Deutschland GmbH
|
Sponsoring Entity
Sanofi-Aventis Deutschland GmbH
|
Biosensor for determining an analyte concentration | ||
Patent #
US 10,067,082 B2
Filed 06/29/2016
|
Current Assignee
Ascensia Diabetes Care Holdings AG
|
Sponsoring Entity
Ascensia Diabetes Care Holdings AG
|
Underfill management system for a biosensor | ||
Patent #
US 10,175,194 B2
Filed 11/19/2015
|
Current Assignee
Ascensia Diabetes Care Holdings AG
|
Sponsoring Entity
Ascensia Diabetes Care Holdings AG
|
Determining analyte concentration from variant concentration distribution in measurable species | ||
Patent #
US 10,190,150 B2
Filed 03/10/2015
|
Current Assignee
Ascensia Diabetes Care Holdings AG
|
Sponsoring Entity
Ascensia Diabetes Care Holdings AG
|
Biological sample measuring device | ||
Patent #
US 10,241,069 B2
Filed 10/30/2015
|
Current Assignee
PHC Holdings Corporation
|
Sponsoring Entity
PHC Holdings Corporation
|
Analyzing device, sensor testing device, testing method and computer-readable storage medium | ||
Patent #
US 10,295,495 B2
Filed 02/18/2016
|
Current Assignee
ARKRAY Inc
|
Sponsoring Entity
ARKRAY Inc
|
Analyte measurement method and system | ||
Patent #
US 10,429,337 B2
Filed 11/03/2016
|
Current Assignee
LifeScan IP Holdings LLC
|
Sponsoring Entity
LifeScan IP Holdings LLC
|
Electrochemical-sensor design | ||
Patent #
US 6,841,052 B2
Filed 05/21/2001
|
Current Assignee
Ascensia Diabetes Care Holdings AG
|
Sponsoring Entity
Bayer Corporation
|
Method and apparatus for electrochemical measurement using statistical technique | ||
Patent #
US 6,576,117 B1
Filed 01/29/2001
|
Current Assignee
ARKRAY Inc
|
Sponsoring Entity
ARKRAY Inc
|
Electrochemical-sensor design | ||
Patent #
US 20010042683A1
Filed 12/08/2000
|
Current Assignee
Ascensia Diabetes Care Holdings AG
|
Sponsoring Entity
Ascensia Diabetes Care Holdings AG
|
Electrochemical biosensor | ||
Patent #
US 5,798,031 A
Filed 05/12/1997
|
Current Assignee
Bayer Corporation
|
Sponsoring Entity
Bayer Corporation
|
Method for detecting source of error in an amperometric measuring cell | ||
Patent #
US 5,611,909 A
Filed 12/21/1995
|
Current Assignee
Dragerwerk AG
|
Sponsoring Entity
Dragerwerk AG
|
Apparatus for reduction of bias in amperometric sensors | ||
Patent #
US 5,620,579 A
Filed 05/05/1995
|
Current Assignee
Bayer Corporation
|
Sponsoring Entity
Bayer Corporation
|
Monoclonal antibodies to hygromycin B and the method of making the same | ||
Patent #
US 5,620,890 A
Filed 03/14/1995
|
Current Assignee
United States Department Of Agriculture, United States Incorporated
|
Sponsoring Entity
United States Department Of Agriculture, United States Incorporated
|
Method for reducing bias in amperometric sensors | ||
Patent #
US 5,653,863 A
Filed 05/09/1996
|
Current Assignee
Bayer Healthcare LLC
|
Sponsoring Entity
Bayer Corporation
|
Fluid testing sensor for use in dispensing instrument | ||
Patent #
US 5,660,791 A
Filed 06/06/1996
|
Current Assignee
Ascensia Diabetes Care Holdings AG
|
Sponsoring Entity
Bayer Corporation
|
Method of making and amperometric electrodes | ||
Patent #
US 5,429,735 A
Filed 06/27/1994
|
Current Assignee
BAAYER CORPORATION
|
Sponsoring Entity
BAAYER CORPORATION
|
Biosensor and measuring apparatus using the same | ||
Patent #
US 5,320,732 A
Filed 06/11/1993
|
Current Assignee
Matsushita Electric Industrial Company Limited
|
Sponsoring Entity
Matsushita Electric Industrial Company Limited
|
Biosensor and a method for measuring a concentration of a substrate in a sample | ||
Patent #
US 5,264,103 A
Filed 10/15/1992
|
Current Assignee
Panasonic Corporation
|
Sponsoring Entity
Matsushita Electric Industrial Company Limited
|
Biosensor and a process for preparation thereof | ||
Patent #
US 5,120,420 A
Filed 11/27/1989
|
Current Assignee
Matsushita Electric Industrial Company Limited
|
Sponsoring Entity
Matsushita Electric Industrial Company Limited
|
28 Claims
- 1. A method of determining the concentration of an analyte in a fluid test sample, the method comprising the acts of:
providing an electrochemical sensor adapted to measure the analyte in the fluid test sample, the electrochemical sensor having a counter electrode and a working electrode; sufficiently covering the counter and working electrodes of the electrochemical sensor with the fluid test sample; applying a first potential between the counter electrode and working electrode for a first predetermined time period; measuring the current between the counter electrode and working electrode at a plurality of intervals during the first predetermined time period; recording the times of at least one measurement during the first predetermined time period; removing or substantially reducing the first potential between the counter electrode and working electrode for a second predetermined time period; applying a second potential between the counter electrode and working electrode for a third predetermined time period; measuring the current between the counter electrode and working electrode at least once during the third predetermined time period; determining the concentration of the analyte in the fluid test sample as a function of the current measured; calculating an index as a mathematical function of the following variables;
a measured current of the first predetermined time period a recorded time of the first predetermined time period, and a measured current of the third predetermined time period;comparing the index to at least one predetermined parameter related to the determined concentration of analyte in the fluid test sample to identify when a bias, if any, exceeds a predetermined threshold; and displaying either an error signal or an analyte concentration depending on the comparison between the index and the at least one predetermined parameter. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)
- 22. A method of determining the concentration of an analyte in a fluid test sample, the method comprising the acts of:
providing an electrochemical sensor adapted to measure the analyte in the fluid test sample, the electrochemical sensor having a counter electrode and a working electrode; sufficiently covering the counter and working electrodes of the electrochemical sensor with the fluid test sample; applying a first potential between the counter electrode and working electrode for a first predetermined time period; measuring the current between the counter electrode and working electrode at least once during the first predetermined time period; recording the times of the at least one measurement during the first predetermined time period; removing or substantially reducing the first potential between the counter electrode and working electrode for a second predetermined time period; applying a second potential between the counter electrode and working electrode for a third predetermined time period; measuring the current between the counter electrode and working electrode at least once during the third predetermined time period; determining the concentration of the analyte in the fluid test sample as a function of the current measured; calculating an index (I) by solving the equation;
I=(Irt/Ibmax)*Tbmaxwhere Irt=a selected measurement of the current during the third predetermined time period, Ibmax=the highest current measured during the first predetermined time period, and Tbmax=the time of the highest measured current is measured during the first predetermined time period; comparing the index to at least one predetermined parameter related to the determined concentration of analyte in the fluid test sample to identify when a bias, if any, exceeds a predetermined threshold; and displaying either an error signal or an analyte concentration depending on the comparison between the index and the at least one predetermined parameter. - View Dependent Claims (23, 24, 25)
- 26. A method of determining the concentration of an analyte in a fluid test sample, the method comprising the acts of:
providing an electrochemical sensor adapted to measure the analyte in the fluid test sample, the electrochemical sensor having a counter electrode and a working electrode; sufficiently covering the counter and working electrodes of the electrochemical sensor with the fluid test sample; applying a first potential between the counter electrode and working electrode for a first predetermined time period; measuring the current between the counter electrode and working electrode at a plurality of times during the first predetermined time period; recording the time of at least one measurement during the first predetermined time period; removing or substantially reducing the first potential between the counter electrode and working electrode for a second predetermined time period; applying a second potential between the counter electrode and working electrode for a third predetermined time period; measuring the current between the counter electrode and working electrode at least one during the third predetermined time period, determining the concentration of the analyte in the fluid test sample as a function of the current measured; calculating an index as a mathematical function of the following variables;
a recorded time of the first predetermined time period, and a measured current of the third predetermined time period;comparing the index to at least one predetermined parameter related to the determined concentration of analyte in the fluid test sample to identify when a bias, if any, exceeds a predetermined threshold; and displaying either an error signal or an analyte concentration depending on the comparison between the index and the at least one predetermined parameter. - View Dependent Claims (27, 28)
1 Specification
This application claims the benefit of the U.S. Provisional Application 60/446,223, filed on Feb. 11, 2003, which is hereby incorporated by reference in its entirety.
The present invention relates to methods using biosensors and, more specifically, methods of detecting bias in determining an analyte concentration in a fluid test sample caused by incompletely filled electrochemical sensors.
The quantitative determination of analytes in body fluids is of great importance in the diagnoses and maintenance of certain physiological abnormalities. For example, lactate, cholesterol and bilirubin should be monitored in certain individuals. In particular, determining glucose in body fluids is important to diabetic individuals who must frequently check the glucose level in their body fluids to regulate the glucose intake in their diets. While the remainder of the disclosure herein will be directed towards determining glucose, it is to be understood that the methods of this invention may be used for determining other analytes upon selection of an appropriate enzyme.
There have been various methods implemented in the past that use biosensors (e.g., biochemical sensors) to determine the quantity of a specific component (analyte) in a fluid sample. Some examples of these biosensors, including electrochemical sensors, are disclosed in U.S. Pat. Nos. 5,120,420, 5,264,103 and 5,620,579, and U.S. Publication No. 20010042683.
Some drawbacks with existing methods that use electrochemical sensors may occur when an insufficient amount of the fluid sample is present. These drawbacks occur when counter and working electrodes of the electrochemical sensors are not completely covered with the fluid sample, resulting in an incomplete current flowing across the electrodes. Since the amount of analyte (e.g., glucose) detected by the electrochemical sensor is directional proportional to the current flowing through the detection meter, failure to completely cover the electrochemical sensor'"'"'s electrodes may result in a bias of the blood sample'"'"'s analyte (e.g., glucose concentration).
It would be desirable to provide a method that detects when there is an insufficient amount of fluid sample and report such a condition as an error to the user. It also would be desirable to provide a method that detects electrochemical sensors with an abnormal rehydration process, because of an insufficient sample to completely re-hydrate the chemistry of the electrochemical sensor. It would be desirable to provide a method that determines an insufficient amount of fluid sample exists even when the electrodes of the electrochemical sensors are sufficiently covered. It would also be desirable to report such conditions as errors to the user if the bias of the analyte concentration exceeds a predetermined threshold caused by, for example, solution movement in incompletely filled sensors or abnormal re-hydration kinetics.
According to one method of determining the concentration of an analyte in a fluid test sample, an electrochemical sensor adapted to measure the analyte in the fluid test sample is provided. The electrochemical sensor has a counter electrode and a working electrode. The counter and working electrodes of the electrochemical sensor are sufficiently covered by the fluid test sample. A first potential is applied between the counter electrode and working electrode for a first predetermined time period. The current is measured between the counter electrode and working electrode at a plurality of times during the first predetermined time period. The times of the measurements during the first predetermined time period is recorded. The first potential is removed or substantially reduced between the counter electrode and working electrode for a second predetermined time period. A second potential is applied between the counter electrode and working electrode for a third predetermined time period. The current is measured between the counter electrode and working electrode at least once during the third predetermined time period.
The concentration of the analyte in the fluid test sample is determined as a function of the current measured. An index is calculated using at least two of the following: a measured current and recorded time of the first predetermined time period, and the measured current of the third predetermined time period. The index is compared to at least one predetermined parameter related to the determined concentration of analyte in the fluid test sample to identify when a bias, if any, exceeds a predetermined threshold. An error signal or an analyte concentration is displayed depending on the comparison between the index and the at least one of the predetermined parameter.
According to another method of determining the concentration of an analyte in a fluid test sample, an electrochemical sensor adapted to measure the analyte in the fluid test sample is provided. The electrochemical sensor has a counter electrode and a working electrode. The counter and working electrodes of the electrochemical sensor are sufficiently covered by the fluid test sample. A first potential is applied between the counter electrode and working electrode for a first predetermined time period. The current is measured between the counter electrode and working electrode a plurality of times during the first predetermined time period. The times of the measurements during the first predetermined time period is recorded. The first potential is removed or substantially reduced between the counter electrode and working electrode for a second predetermined time period. A second potential is applied between the counter electrode and working electrode for a third predetermined time period. The current is measured between the counter electrode and working electrode at least once during the third predetermined time period.
The concentration of the analyte in the fluid test sample is determined as a function of the current measured. An index (I) is calculated by solving the equation:
I=(Irt/Ibmax)*Tbmax
- where
- Irt=the last measurement of the current during the third predetermined time period,
- Ibmax=the highest current measured during the first predetermined time period, and
- Tbmax=the time of the highest measured current is measured during the first predetermined time period.
The index is compared to at least one predetermined parameter related to the determined concentration of analyte in the fluid test sample to identify when a bias, if any, exceeds a predetermined threshold. An error signal or an analyte concentration is displayed depending on the comparison between the index and the at least one of the predetermined parameter.
According to a further method of determining the concentration of an analyte in a fluid test sample, an electrochemical sensor adapted to measure the analyte in the fluid test sample is provided. The electrochemical sensor has a counter electrode and a working electrode. The counter and working electrodes of the electrochemical sensor are sufficiently covered by the fluid test sample. A first potential is applied between the counter electrode and working electrode for a first predetermined time period. The current is measured between the counter electrode and working electrode at a plurality of times during the first predetermined time period. The times of the measurements during the first predetermined time period is recorded. The first potential is removed or substantially reduced between the counter electrode and working electrode for a second predetermined time period. A second potential is applied between the counter electrode and working electrode for a third predetermined time period. The current is measured between the counter electrode and working electrode at least once during the third predetermined time period.
The concentration of the analyte in the fluid test sample is determined as a function of the current measured. An index is calculated using a measured current and recorded time of the first predetermined time period, and the measured current of the third predetermined time period. The index is compared to at least one predetermined parameter related to the determined concentration of analyte in the fluid test sample to identify when a bias, if any, exceeds a predetermined threshold. An error signal or an analyte concentration is displayed depending on the comparison between the index and the at least one of the predetermined parameter.
According to yet another method of determining the concentration of an analyte in a fluid test sample, an electrochemical sensor adapted to measure the analyte in the fluid test sample is provided. The electrochemical sensor has a counter electrode and a working electrode. The counter and working electrodes of the electrochemical sensor are sufficiently covered by the fluid test sample. A potential is applied between the counter electrode and working electrode for a predetermined time period. The current is measured between the counter electrode and working electrode at a plurality of times during the predetermined time period. The times of the measurements during the predetermined time period is recorded. The concentration of the analyte in the fluid test sample is determined as a function of the current measured. An index is calculated using a selected measured current and recorded time of the predetermined time period. The index is compared to at least one predetermined parameter related to the determined concentration of analyte in the fluid test sample to identify when a bias, if any, exceeds a predetermined threshold. An error signal or an analyte concentration is displayed depending on the comparison between the index and the at least one of the predetermined parameter.
While the invention is susceptible to various modifications and alternative forms, specific embodiments thereof has been shown by way of example in the drawing and will herein be described in detail. It should be understood, however, that it is not intended to limit the invention to the particular forms disclosed but, on the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention as defined by the appended claims.
The present invention relates to methods using biosensors and, more specifically, methods of detecting bias in determining the concentration of an analyte caused by incompletely filled biosensors (i.e., an under-fill condition). By detecting high-biased analyte results caused by, for example, sample movement inside an incompletely filled biosensor, the biosensor'"'"'s performance can be improved. Other abnormal conditions may include an insufficient sample to completely dissolve the sensor'"'"'s chemistry. The biosensor'"'"'s performance is improved by reporting such results as an under-filled error to the user. It is desirable to be able to detect and report an under-filled error that occurs when one of the electrodes of an under-filled sensor is not contacted with the fluid test sample. An example of such a condition is when the fluid test sample is sufficient to make contact between the working the counter electrodes, but insufficient to completely fill the capillary (e.g., about 3.5 μL). The bias may occur when blood moves up the capillary when the sensor is pulled away from the whole blood samples due to the breaking of the meniscus and capillary action. The magnitude of the bias on the final glucose reading depends on the percentage of blood volume in the sensor capillary and the time when the sensor is pulled away from the sample drop.
As discussed above, the analyte to be tested may be glucose in a whole blood sample. The analyte (e.g., glucose) concentration of the fluid test sample (e.g., whole blood sample) may be determined using an amperometric monitoring system.
Electrochemical Sensor
To determine the glucose concentration in a whole blood sample, an electrochemical sensor according to one embodiment is provided. It is important that the electrochemical sensor provides reliable and reproducible measurements. According to one embodiment, the electrochemical sensor in the present invention may be that described in U.S. patent application published as 20010042683 on Nov. 22, 2001 and entitled Electrochemical-Sensor Design, which is incorporated by reference in its entirety.
An example of an electrochemical sensor described in U.S. patent application published as 20010042683 is depicted in FIG. 1. Referring to
The function of the reaction layer 44 is to convert glucose, or another analyte in the fluid test sample, stoichiometrically into a chemical species which is electrochemically measurable, in terms of electrical current it produces, by the components of the electrode pattern. The reaction layer 44 generally contains a biosensing or reagent material, such as an enzyme, and an electron acceptor. More specifically, the reaction layer 44 contains an enzyme that reacts with the analyte to produce mobile electrons on the electrode pattern and an electron acceptor (e.g., a ferricyanide salt) to carry the mobile electrons to the surface of the working electrode. The electron acceptor may be referred to as a mediator in which the mediator is reduced in response to a reaction between the analyte and the enzyme. The enzyme in the reaction layer may be combined with a hydrophilic polymer, such as polyethylene oxide. An enzyme that may be used to react with glucose is glucose oxidase. It is contemplated that other enzymes may be used such as glucose dehydrogenase.
The two portions 39, 40 of the electrode pattern provide the respective working and counter electrodes necessary to electrochemically determine the analyte. The working electrode typically comprises an enzyme that reacts with the analyte. The working and counter electrodes may be configured such that the major portion of the counter electrode is located downstream (in terms of the direction of fluid flow along the flow path) from the exposed portion of the working electrode 39a. This configuration allows the test fluid sample to completely cover the exposed portion of the working electrode for all cases in which an undetected partial fill has occurred.
Counter electrode sub-element 40a, however, is positioned up-stream from working electrode upper element 39a so that when an inadequate amount of the test fluid sample (e.g., a whole blood sample) to completely cover the working electrode enters the capillary space, an electrical connection forms between counter electrode sub-element 40a and exposed portion of the working electrode 39a due to the conductivity of the whole blood sample. The area of the counter electrode, however, that is available for contact by the whole blood sample is so small that only a very weak current can pass between the electrodes and, thus, through the current detector. By programming the current detector to give an error signal when the received signal is below a certain pre-determined level, the sensor device informs the user that insufficient blood has entered the sensor'"'"'s cavity and that another test should be conducted. While the particular dimensions of the electrodes are not critical, the area of the counter electrode sub-element 40a is typically less than about 10% than that of the working electrode and, more specifically, less than about 6%. This element should be made as small as possible in view of the restraints of the screen printing process.
It is also contemplated that the reaction layer 44 may be removed from contact with counter electrode sub-element 40a. This is accomplished by producing a screen that does not print reagent ink over the counter electrode sub-element 40b. This serves the purpose of starving the sub-element for reagent, thereby not allowing it to function as a proper counter electrode, so that an error condition is achieved when the test fluid sample fails to contact the bulk of the counter electrode 40. While sub-element 40a is depicted as being physically connected to, and therefore part of, the counter electrode 40, such physical connection is not critical. Such sub-element may be physically disconnected from the rest of the counter electrode provided that it has its own connector and the sensor is equipped with a third contact to the detector.
The working and counter electrodes include electrode ink. The electrode ink, which is generally about 14μ (0.00055″) thick, typically contains electrochemically active carbon. Components of the conductor ink may be a mixture of carbon and silver that is chosen to provide a low chemical resistance path between the electrodes and the meter with which they are in operative connection via contact with the conductive pattern at a fish-tail end 45 of the sensor. The counter electrode may be comprised of silver/silver chloride although carbon is preferred. To enhance the reproducibility of the meter reading, the dielectric pattern insulates the electrodes from the fluid test sample except in a defined area near the center of the electrode pattern 43. A defined area is important in this type of electrochemical determination because the measured current depends on the analyte concentration and the area of the reaction layer that is exposed to the analyte-containing test sample.
A typical dielectric layer 42 comprises a UV-cured acrylate modified polymethane that is about 10μ (0.0004″) thick. A lid or cover 46 is adapted to mate with the base to form a space to receive the fluid test sample in which the counter and working electrodes are situated. The lid 46 provides a concave space 48, and is typically formed by embossing a flat sheet of deformable material. The lid 48 is punctured to provide an air vent 50 and joined to the base 36 in a sealing operation. The lid and base can be sealed together by sonic welding in which the base 36 and lid 46 are first aligned and then pressed together between a vibratory heat sealing member or horn and a stationary jaw. The horn is shaped such that contact is made only with the flat, non-embossed regions of the lid. Ultrasonic energy from a crystal or other transducer is used to excite vibrations in the metal horn. This mechanical energy is dissipated as heat in the polymeric joint allowing the bonding of the thermoplastic materials. The embossed lid and base may be joined by using an adhesive material on the underside of the lid. The method of joining the lid and base are more fully described in U.S. Pat. No. 5,798,031 which is incorporated herein by reference in its entirety.
Suitable materials for the insulating base 36 include polycarbonate, polyethylene terephthalate, dimensionally-stable vinyl and acrylic polymers, and polymer blends such as polycarbonate/polyethylene terephthalate and metal foil structures (e.g., a nylon/aluminum polyvinyl chloride laminate). The lid is typically fabricated from a deformable polymeric sheet material such as polycarbonate, or an embossable grade of polyethylene terephthalate, glycol modified polyethylene terephthalate or a metal foil composition (e.g., an aluminum foil structure). The dielectric layer may be fabricated from an acrylate-modified polyurethane that is curable by UV light or moisture or a vinyl polymer that is heat curable.
It is contemplated that other electrochemical sensors may be used in the present invention. Examples of an electrochemical sensor that can be used to measure glucose concentrations are those used in Bayer Corporation'"'"'s Glucometer DEX® and ELITE® systems. More details on such an electrochemical sensor may be found in U.S. Pat. Nos. 5,120,420 and 5,320,732 which are both incorporated by reference in their entirety. One or more of the electrochemical sensors may be purchased from Matsushita Electric Industrial Company. Another electrochemical sensor is disclosed in U.S. Pat. No. 5,798,031, which is incorporated by reference in its entirety. A further example of an electrochemical sensor that may be used in an amperometric monitoring system is disclosed in U.S. Pat. No 5,429,735. It is contemplated that other biosensors may be used in the present invention.
The electrochemical sensors may be located in a blood glucose sensor dispensing instrument that is adapted to have loaded therein a sensor pack that includes a plurality of sensors or testing elements. Each of the sensors is adapted to be ejected from the sensor pack. One example of a sensor pack loaded in a sensor dispensing instrument is disclosed in U.S. Pat. No. 5,660,791. It is contemplated that the electrochemical sensors may be stored in other apparatus such as bottles.
Methods of the Present Invention
A method of determining the concentration of an analyte in a fluid test sample of the present invention may include using one of the electrochemical sensors described above (e.g., sensor 34). The electrochemical sensor includes a counter electrode and a working electrode. It is contemplated that other electrochemical sensors may be used than described in connection with
Referring to
The current is measured between the counter electrode and working electrode at a plurality of intervals, and the times of the measurements are recorded during the first predetermined time period during step 130. The first predetermined time period is generally from about 2 to about 30 seconds and, more typically, from about 5 to about 15 seconds. The current during the first predetermined time period may be measured in regular intervals that may vary in duration. For example, the current during the first predetermined time period is generally measured in regular intervals of from about 0.1 to about 3 seconds, and, more typically, from about 0.2 to about 0.5 seconds. During the measuring of the current, the time of such measurements is recorded. The first predetermined time period is referred to as the “burn-off” period.
During step 140, the first potential between the counter electrode and working electrode is removed or substantially reduced for a second predetermined time period. The second predetermined time period is generally from about 2 to about 20 seconds and, more typically, from about 5 to about 15 seconds. The second predetermined time period is referred to as the “wait” or “incubation” period.
A second potential between the counter electrode and working electrode is applied for a third predetermined time period in step 150. The second potential is generally from about 100 to about 600 mV and, more typically, from about 300 to about 500 mV. The current is measured between the counter and working electrodes during the third predetermined time period in step 160. The third predetermined time period is generally from about 2 to about 30 seconds and, more typically, from about 5 to about 15 seconds. The current during the third predetermined time period may be measured in regular intervals that may vary in duration. For example, the current is generally measured in regular intervals of from about 0.1 to about 3 seconds, and, more typically, from about 0.2 to about 0.5 seconds. The third predetermined time period is referred to as “read” period. According to another method, the second and third predetermined time periods may be eliminated.
According to one method, the concentration of the analyte is determined in the fluid test sample as a function of the current measured during the third predetermined time period in step 170. It is contemplated, however, that the concentration of the analyte may be determined as a function of the current measured during the first predetermined time period.
To assist in determining if an under-fill condition is present when the electrodes of the electrochemical sensor are not sufficiently covered by the test fluid sample, the analyte concentration may be compared to at least one factor, such as the k-factor and/or read-to-burn ratio. The electrochemical sensor is configured so that in the event of an under-fill condition, the result will be affirmative as opposed to a neutral response, i.e. a failure of the detector to give, any signal. Thus, for example, when the amount of the test fluid sample that enters the capillary space is sufficient to cover the counter electrode sub-element 40a or 40b and that portion of the working electrode 39a which lies upstream from the main portion of the counter electrode 40, the detector will sense a current but the current will be weaker than if the working and counter electrodes were completely or sufficiently covered with the test fluid sample. The detector may be connected with the reading means to display an error signal to the user when an under-fill condition occurs.
There are provided means for sensing certain characteristics of the current over time that are used along with the absolute current level to determine if an error condition has occurred. This is accomplished by algorithmically programming the meter to detect the under-fill condition by measuring the current at a definite time period after the test fluid has electrically connected the sub-element of the counter electrode with the working electrode. The ratio of the currents for the two measurements is used to determine if the sensor has filled properly. For example, the current is measured at 5 and 10 seconds after applying the driving potential to the circuit, and these two currents are converted into a ratio. This ratio and the current reading at 10 seconds are used to determine if the sensor'"'"'s capillary space has filled properly.
A sample calculation is as follows: three current measurements are made during the test sequence according to one method: (a) at the end of an initial period known as the “burn-off” period in which the driving potential has been applied for a first predetermined time period (e.g., 10 seconds denoted as Ib10); (b) when the potential is applied and measured during the third predetermined time interval or “read” period at, for example, 5 seconds (Ir5), and (c) at the end of the third predetermined time period (e.g., 10 seconds) known as the “read” period denoted as Ir10. It is contemplated that the time periods may vary from the exemplary times above. Two parameters may be determined from these three current measurements. At least one of these two parameters is used to determine if the sensor'"'"'s capillary space has filled properly. The first parameter is the decay factor, k, which describes the shape of current time course. The second parameter is a ratio that characterizes the rate of decay in the current level during the read phase.
The decay factor, k, is defined as:
k=ln(Ir5)−ln(Ir10)/(ln(10)−ln(5)) Equation A
The Read-to-Burn ratio, R/B, is defined as:
R/B=Ir10/Ib10 Equation B
One example of criteria for an under-fill condition using these two parameters may be as follows:
If k<0.227 or k>0.497; or (1)
If R/B<0.263 or R/B>1.263. (2)
It is contemplated that the numbers of this criteria may vary for the decay factor, k, and the Read-to-Burn ratio, R/B, in determining whether an under-fill condition is present. An under-filled sensor produced the following three current measurements:
An example using these parameters with an under-filled condition is as follows:
Ib10=505.1 nA, Ir5=656.5 nA, and Ir10=561.8 nA.
The decay factor and Read-to-Burn ratio were calculated from these current measurements:
Decay factor
Read-to-Burn ratio
R/B=Ir10/Ib10=561.8/505.1=1.11
These two parameters were used to detect the following error conditions:
- k<0.227 or k>0.497 at this glucose readback level. True, because k=9.22<0.227;
- R/B<0.263 or R/B>1.263 at this glucose readback level. False, because R/B=1.11>0.263 and <1.263.
By providing a device which gives a positive (as opposed to a neutral) response in the event of an under-fill condition when the electrodes of the electrochemical sensor are not sufficiently covered by the test fluid sample, the user will recognize that the abortive function of the test is a result of too little blood entering the capillary space, rather than some other malfunction having caused the anomalous result. Such a comparison works well when the counter electrode of an under-filled sensor is not contacted with the blood sample. The counter electrode (without movement of the whole blood sample) is not typically contacted with the blood sample in DEX system when the whole blood sample is below about 2.5 μL or 2.0 μL.
To improve the detection of certain under-fill conditions (e.g., a condition where the whole blood sample is moving such that the sensor capillary is incompletely filled but the whole blood sample is in contact with the counter electrode), an index is calculated in the present invention. An index is calculated in step 190 according to one process by using at least two of the following: one measured current and recorded time during the first predetermined time period, and at least one measured current of the third time period.
One example of an index that may be used in the present invention is by solving Equation C which uses all three variables:
Index (I)=(Irt/Ibmax)*Tbmax Equation C
- where:
- Irt=a current measured during the first or third predetermined time period (e.g., the last measurement of the current during the third predetermined time period),
- Ibmax=the highest current measured during the first predetermined time period, and
- Tbmax=the time when the highest current is measured during the first predetermined time period.
It is contemplated that other equations may be used to determine an index in the present invention that may use less than the above three variables. For example, two of these variables (a measured current and recorded time of the first determined time period and the measured current of the third predetermined time period) may be used to determine an appropriate index. One example of such is to determine an appropriate index by using the slope of the measured current and recorded time of the first determined time period. Alternatively, it is contemplated that other indices may be created using the slope of (a) the measured current of the first predetermined time period and the measured current of the third predetermined time period, or (b) the recorded time of the first predetermined time period and the measured current of the third predetermined time period.
In step 200, the index is compared to at least one predetermined parameter related to the determined concentration of analyte in the fluid test sample to identify when the bias exceeds a predetermined threshold, which is obtained from step 180. The predetermined parameter(s) is typically stored in the meter.
Depending on whether the index is within at least one of the predetermined parameter, either an error signal is displayed (step 210) or the analyte concentration is displayed (step 220). According to one process, an error signal is displayed when the index is not within the at least one predetermined parameter and the analyte concentration is displayed when the index is within the at least one predetermined parameter. Alternatively, the error signal may be displayed when the index is within the at least one predetermined parameter and the analyte concentration is displayed when the index is not within the at least one predetermined parameter.
An example of determining an index and comparing it with a predetermined parameter is shown in
The index from step 330 is compared in step 350 to a predetermined parameter taken from step 340. In this example, the predetermined parameter is 1.5. It is contemplated that the predetermined parameter may be different than shown in step 340. The predetermined parameter is related to the level of glucose concentration. If the index is greater than the predetermined parameter of 1.5, then a display error is indicated at step 360. If the index is less than or equal to 1.5, then the analyte concentration will be calculated and reported to the user in step 370.
The method for determining the analyte concentrations (e.g., glucose concentrations) may be performed in disposable self-testing systems. The disposable self-testing systems are often used by end consumers, especially those who are diabetic. Alternatively, the method for determining the analyte concentrations (e.g., glucose concentrations) may be performed in clinical analyzers. Clinical analyzers are often used in hospitals or clinics.
The testing end of the sensor is adapted to be placed into contact with the fluid sample (e.g., a whole blood sample) to be tested. The whole blood sample may be generated by a lancing device such as a microlet. The lancing device may obtain blood by, e.g., pricking a person'"'"'s finger. According to one process, the whole blood sample may be prepared for testing by (a) removing the electrochemical sensor from a packet, (b) placing the electrochemical sensor into a glucose concentration measuring instrument, (c) generating a whole blood sample, and (d) bringing the sensor and the whole blood sample into contact wherein the blood is generally drawn into the sensor by capillary action.
According to one process, a whole blood sample is introduced into the space via an introducing port. Gas is discharged from the space by the inflow of the whole blood sample via a discharge port. It is believed that the glucose in the whole blood sample reacts with the enzyme (e.g., glucose oxidase carried on the electrodes to produce gluconic acid). A voltage is applied (e.g., 600 mV) between the electrodes and the electrode for measurement is polarized in the anode direction. By applying a voltage in the anode direction, an oxidizing current for the produced hydrogen peroxide is obtained. This current level corresponds to the concentration of glucose in the whole blood sample.
Several experiments were performed to show the effects of the glucose concentrations of a whole blood sample using a under-filled test sensors (see Table 1). Also, several experiments were performed using a whole blood sample in a proper filled condition (see Table 2).
Table 1 Testing Procedure
Whole blood samples of 3 μL were tested 15 times with various solution movement during the testing. In other words, some samples moved slightly, while others were moved to a greater extent. The whole blood samples were taken from the same source and, thus, had about the same glucose concentration.
The testing was performed using the following steps. First, a positive potential of 400 mV was applied between the working electrode and the counter electrode of the electrochemical sensor. The electrochemical sensor that was used was taken from Bayer Corporation'"'"'s Glucometer DEX® system. A 3 μL whole blood sample was added to and contacted the electrochemical sensor. The current was measured between the working and the counter electrodes every 0.3 second for 10 seconds during the “burn” period. This current is referred to as the burn current. The respective times were also recorded that corresponded to the measurements of the burn current. The potential between the working and counter electrodes was removed, resulting in an open circuit for a time period of 10 seconds. This time period is referred to as the “wait” or “incubation” period. A positive potential of 400 mV was re-applied between the working and the counter electrodes of the electrochemical sensor. The current was measured between the working electrode and the counter electrode every 0.3 second for 10 seconds during the “read” period. This current is referred to as the read current. The read current was used to determine the glucose concentration of the whole blood sample.
This glucose calculation was then compared to predetermined parameters of k-factor and the read-to-burn ratio to determine if the blood sample amount was not sufficient. These ratios were calculated in the same manner as described above in the application in Equations A and B.
The index was calculated as described above in Equation C and then compared to a predetermined index of 1.5. If the index was greater than 1.5, then an error was displayed. If the index was less than or equal to 1.5, then the analyte concentration was reported. The test results are shown in Table 1 below.
The % bias from 10 μL, which is an example of 100% filled condition, was calculated as follows in Equation D:
(Glucoseany underfil volume−Glucose10 uL)/Glucose10 uL*100 Equation D
The 10 μL sample was used to ensure that the sensors were 100% filled.
As can be seen in Table 1 above, Replicate Nos. 4, 9 and 15 had indices greater than 1.5 and, thus, produced an error signal to the user. On the other hand, Replicate Nos. 1–3, 5–8 and 10–14 did not have indices greater than 1.5 and, thus, did not display an error signal to the user. This test indicates that when a sensor is incompletely filled (such as with a 3 μL whole blood sample), then high biased results may occur that are uncacceptable. This was confirmed when Replicate Nos. 4, 9 and 15, independent of the index and the resulting error signal, had % biases greater than 10%. In these examples, the decay factor, k, and the Read-to-Burn ratio, R/B, would be within their normal boundaries in determining whether an under-fill condition is present because the counter and working electrodes would be sufficiently covered with a 3 μL whole blood sample. In other words, using k and/or R/B would not have detected the high biased results.
Table 2 Testing Procedure
Whole blood samples of 10 μL were tested 15 times without any solution movement during sampling. The whole blood samples were taken from the same source and, thus, had about the same glucose concentration. The testing procedure was the same as set forth above in the testing procedure of Table 1.
As can be seen in Table 2 above, none of the Replicate Nos. 1–15 had indices greater than 1.5 and, thus, none produced an error signal to the user. This showed that a completely filed whole blood sample without solution movement did not produce an error signal to the user using the calculated index and the predetermined parameter of 1.5.
While particular embodiments and applications of the present invention have been illustrated and described, it is to be understood that the invention is not limited to the precise construction and compositions disclosed herein and that various modifications, changes, and variations may be apparent from the foregoing descriptions without departing from the spirit and scope of the invention as defined in the appended claims.